John Rickard
Cardiovascular Disease · Baltimore, MDNPI 1083880876
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $71,862 of the $108,917 with a category attached, or 66.0%. 18 manufacturers reported payments, led by Abbott at 57.7% of the total. Reporting peaked in 2019 at $51,119 and has fallen 96.3% since, to $1,875 in 2025. Among cardiovascular disease clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 194 payments — averaging $561.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$63K
- Medtronic$28K
- Boston Scientific$17K
- Biosense Webster, Inc.$668
- Philips North America LLC$159
- Impulse Dynamics (USA) Inc.$152
- plus $549 from 12 others
Across 11 payments — averaging $6890.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$76K
What the payments were for
- Consulting fees$71,86266%
- Speaking & faculty fees$24,77523%
- Travel & lodging$6,7776%
- Food & beverage$5,5045%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 54 | $62,887 |
| Medtronic(2 entities) | 73 | $27,789 |
| Boston Scientific | 22 | $16,714 |
| Biosense Webster, Inc. | 6 | $668 |
| Philips North America LLC | 3 | $159 |
| Impulse Dynamics (USA) Inc. | 2 | $152 |
| Amgen | 7 | $128 |
| Novartis | 8 | $116 |
| E.r. Squibb & Sons, L.L.C. | 4 | $62 |
| Novo Nordisk | 3 | $54 |
| Azurity Pharmaceuticals, Inc. | 2 | $36 |
| Pfizer | 3 | $34 |
| EKOS Corporation | 2 | $24 |
| Lexicon Pharmaceuticals, Inc. | 1 | $23 |
| Cardiva Medical, Inc. | 1 | $20 |
| United Therapeutics Corporation | 1 | $19 |
| AstraZeneca | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HeartMate 3 Left Ventricular Dev$22,464
- Quadra Assura CRT Defibrillator$17,670
- Ensite Cardiac Mapping System$11,463
- GENERAL - THERAPIES$6,875
- Allure CRT Pacemaker$4,914
- AMPLATZER Occluders$2,100
- GALLANT$1,650
- Micra$1,083
- HeartMate 3 Left Ventricular Assist Device$1,050
- CardioMEMS HF System$725
- Carto 3$378
- OPTIMIZER$267
- Carto 3 System$199
- ENSITE PRECISION$179
- ARCTIC FRONT ADVANCE$146
- Amplia MRI$114
- Xience Sierra Coronary Stent System$113
- VIGILANT X4 CRT-D$104
How this compares
$108,917 in reported general payments places this provider in the 95th percentile of 507 cardiovascular disease providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 481 | $507,296 |
| XareltoRivaroxaban | 75 | $97,938 |
| Dofetilide | 121 | $29,597 |
| Flecainide Acetate | 169 | $7,844 |
| Metoprolol Succinate | 167 | $2,869 |
| Amiodarone Hcl | 98 | $1,972 |
| Mexiletine Hcl | 16 | $1,653 |
| Metoprolol Tartrate | 135 | $1,097 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 39 | $874 |
| Propafenone Hcl | 11 | $692 |
| Atorvastatin Calcium | 42 | $401 |
| Lisinopril | 20 | $334 |
| SotalolSotalol Hcl | 15 | $321 |
| Rosuvastatin Calcium | 12 | $260 |
| Losartan Potassium | 13 | $113 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $34 | $507,296481 claims |
| Johnson & JohnsonXarelto | $16 | $97,93875 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 507 cardiovascular disease providers in Maryland.
Other cardiovascular disease in Baltimore
- Navin KapurBaltimore$1.5M
- Michael BlahaBaltimore$609K
- Sanjay RajagopalanBaltimore$521K
- Erin MichosBaltimore$257K
- Seth MartinBaltimore$166K
- Erika FellerBaltimore$121K
- Charles CummingsBaltimore$114K
- Christopher DefilippiBaltimore$101K
- David KassBaltimore$90K
- Hiroshi AshikagaBaltimore$90K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.